Novartis Touts Ligelizumab As Xolair Successor In CSU

Filing Planned For 2021

 
• By Kevin Grogan
Dog_Podium
Novartis hopes ligelizumab will be top dog for CSU • Source: Shutterstock

More from Dermatological

More from Therapeutic Category